Sangstat Medical Corporation Report issue

For profit Phase 2 Phase 3
Founded: Fremont CA United States (1988)
Status: Acquired by Genzyme (2003) → now Sanofi-Aventis (2011)

Organization Overview

First Clinical Trial
1999
NCT00035880
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2001

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SangStat Medical

Active Ingredients

Drugs in Phase 3 Trials (1)

gavilimomab (1 trial)

Drugs in Phase 2 Trials (1)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Graft vs Host Disease (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Preleukemia (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2